Connecticut is currently home to 1248 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Quality of Life in Pediatric Patients with Acute Lymphoblastic Leukemia Receiving Maintenance Chemotherapy
NCT03132948
Recruiting
The purpose of the study is to evaluate the impact of exercise on physical activity levels and quality of life in children with acute lymphoblastic leukemia (ALL) receiving maintenance chemotherapy.
Gender:
ALL
Ages:
Between 8 years and 18 years
Trial Updated:
03/17/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Quality of Life
Register for Updates
Stem Cell Ophthalmology Treatment Study II
NCT03011541
Recruiting
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: MD Stem Cells, Westport, Connecticut
Conditions: Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
Register for Updates
Efficacy of Guselkumab in Treating Hailey Hailey Disease
NCT06651489
Recruiting
Hailey-Hailey disease (HHD) is a debilitating genetic skin disorder, affecting mainly body folds with erythema and painful erosions and blisters. Histopathological findings include epidermal hyperplasia, suprabasilar clefting, dyskeratosis and acantholysis of keratinocytes. A final diagnosis of HHD is usually confirmed based on clinical and histopathological findings in line with genetic testing. Several treatment options have been proposed for this chronic and disabling disorder, however, ther... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
03/14/2025
Locations: Church Street Research Unit, Yale Center for Clinical Investigation, New Haven, Connecticut
Conditions: Hailey Hailey Disease
Register for Updates
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy
NCT05989347
Recruiting
The primary objective of the study is to assess metabolic plasma markers of insulin resistance in patients with early-stage HER2-negative breast cancers receiving dapagliflozin concomitant with neoadjuvant therapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Yale Cancer Center Smilow Cancer Hospital, New Haven, Connecticut
Conditions: Breast Cancer, Hyperinsulinism, HER2-negative Breast Cancer
Register for Updates
Written Exposure Therapy for Veterans With SUD and PTSD
NCT05327504
Recruiting
The proposed project will evaluate the efficacy of written exposure therapy (WET) among Veterans engaged in substance use disorder (SUD) treatment, who present with co-occurring posttraumatic stress disorder (PTSD). While SUD treatment programs traditionally do not address PTSD, effective trauma treatments have been used successfully among those with substance use comorbidities. WET is a brief trauma-focused intervention shown to effectively treat PTSD. In a recent acceptability and feasibility... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut
Conditions: Substance Use Disorders, Posttraumatic Stress Disorder
Register for Updates
The DISCOVER INOCA Prospective Multi-center Registry
NCT05288361
Recruiting
The overall objective of this multi-center registry is to identify specific phenotypes of INOCA with both an anatomic evaluation (coronary angiography and intravascular imaging) and physiologic assessment with the Abbott Coroventis Coroflow Cardiovascular System, and to determine long-term outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Ischemia and no Obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction, Coronary Vasospasm, Endothelial Dysfunction, Microvascular Angina, Chest Pain With Normal Coronary Angiography
Register for Updates
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
NCT04422912
Recruiting
A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific Chimeric Antigen Receptor T cells \[CABA-201\]) in subjects with active, pemphigus vulgaris
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Pemphigus Vulgaris
Register for Updates
A Study of GSK5764227 in Participants With Advanced Solid Tumors
NCT06551142
Recruiting
The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of GSK5764227. The study will also see how the levels of GSK5764227 will change over time at different dose amounts when administered alone and in combination with other medicines like carboplatin, cisplatin, atezolizumab, pembrolizumab, durvalumab, bevacizumab, cetuximab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: GSK Investigational Site, New Haven, Connecticut
Conditions: Neoplasms
Register for Updates
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
NCT05908084
Recruiting
The goal of this clinical trial is to compare the number of catheter-free days (CFD) and the rate and severity of any dialysis access-related infections between the ATEV and AVF groups over 12 months in patients with end-stage renal disease (ESRD) needing hemodialysis (HD). Participants will be stratified by location of the vascular access (forearm versus upper arm) and by type of AVF creation procedure planned by the surgeon at randomization (1-stage AVF versus 2-stage AVF). The comparator is... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: End Stage Renal Disease (ESRD)
Register for Updates
A Phase I/II Study of VLS-1488 in Subjects with Advanced Cancer
NCT05902988
Recruiting
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Gastric Adenocarcinoma, Colorectal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Transitional Cell Carcinoma of Bladder, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma, Endometrium Cancer, Chromosomal Instability
Register for Updates
Walnuts and Colon Health
NCT05195970
Recruiting
The purpose of this research study is to examine whether adding walnuts to your diet can have a beneficial effect on the gut bacteria population, inflammatory markers in the blood, and the tissue that lines the inside of the colon.
Gender:
ALL
Ages:
Between 39 years and 75 years
Trial Updated:
03/13/2025
Locations: UConn Health, Farmington, Connecticut
Conditions: Colorectal Cancer, Diet Habit
Register for Updates
Digoxin In Treatment of Alcohol Associated Hepatitis
NCT05014087
Recruiting
Prospective, single center, open label, randomized controlled trial to explore whether digoxin treatment affects cytokine levels as biomarkers of inflammation in patients with acute alcohol associated hepatitis, digoxin administration and dose adjustment. The study intervention will be intravenous digoxin (renal-based dosing for maximum of 28 days) versus no digoxin in an open-label 1:1 randomized allocation of patients with severe acute alcohol associated hepatitis.
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
03/13/2025
Locations: Yale New Haven Hospital, Yale School of Medicine, New Haven, Connecticut
Conditions: Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury, Alcohol-Induced Disorders, Steatohepatitis Caused by Ingestible Alcohol
Register for Updates